PRESS RELEASE published on 01/27/2025 at 15:18, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group discloses a 5.47% interest in Direct Line Insurance Group plc per Form 8.3 to the UK Takeover Code Form 8.3 Disclosure Takeover Code Vanguard Group Direct Line Insurance
BRIEF published on 01/24/2025 at 15:24, 1 year 7 months ago Vanguard Group Discloses Stake in Direct Line Insurance Takeover Code Vanguard Group Stake Disclosure Aviva Direct Line
BRIEF published on 01/24/2025 at 15:24, 1 year 7 months ago Le groupe Vanguard dévoile sa participation dans Direct Line Insurance Groupe Vanguard Code De Prise De Contrôle Divulgation Des Enjeux Aviva Ligne Directe
PRESS RELEASE published on 01/24/2025 at 15:19, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses 5.47% ownership in Direct Line Insurance Group plc per Form 8.3 disclosure Securities Form 8.3 Vanguard Group Ownership Disclosure Direct Line Insurance
BRIEF published on 01/23/2025 at 15:12, 1 year 7 months ago The Vanguard Group Discloses Position in Direct Line Insurance Group Takeover Code Vanguard Group Shareholding Direct Line Insurance Aviva Plc
BRIEF published on 01/23/2025 at 15:12, 1 year 7 months ago Le groupe Vanguard révèle sa position dans Direct Line Insurance Group Actionnariat Groupe Vanguard Code De Prise De Contrôle Aviva Plc Assurance Ligne Directe
PRESS RELEASE published on 01/23/2025 at 15:07, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses 5.48% interest in Direct Line Insurance Group plc. Disclosures in respect of Aviva plc also made Vanguard Group Financial Disclosure Direct Line Insurance Stock Holdings Aviva Plc
BRIEF published on 01/22/2025 at 14:41, 1 year 7 months ago Vanguard Group Discloses Significant Stake in Direct Line Insurance Investment Strategy Takeover Code Vanguard Group Stake Disclosure Direct Line Insurance
BRIEF published on 01/22/2025 at 14:41, 1 year 7 months ago Le groupe Vanguard révèle une participation importante dans Direct Line Insurance Stratégie D'investissement Groupe Vanguard Code De Prise De Contrôle Divulgation Des Enjeux Assurance Ligne Directe
PRESS RELEASE published on 01/22/2025 at 14:36, 1 year 7 months ago Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc The Vanguard Group, Inc. discloses a 5.49% stake in Direct Line Insurance Group plc as of 21 Jan 2025. Also making disclosures regarding Aviva plc Vanguard Group Financial Disclosure Stake Disclosure Direct Line Insurance Aviva Plc
Published on 09/11/2026 at 04:00, 6 hours 42 minutes ago Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 12 hours 17 minutes ago Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 15:20, 19 hours 22 minutes ago MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 19 hours 42 minutes ago All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Published on 09/11/2026 at 10:15, 27 minutes ago TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 1 hour 22 minutes ago Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 1 hour 36 minutes ago ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 1 hour 42 minutes ago Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 07:00, 3 hours 42 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 3 hours 42 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 3 hours 42 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 15 hours 12 minutes ago Availability of the 2026 Interim Financial Report
